The National Institute for Korean Medicine Development (President Koh Hoyoun) announced on August 13 that it will overhaul the user system of the National Korean Medicine Clinical Information Portal (NCKM) and expand the scope of public access to key content, in order to enhance accessibility to research achievements and clinical information in Korean medicine.


NCKM is a national public platform that provides a range of information, including Korean Medicine Standard Clinical Practice Guidelines (CPG), clinical research data, and information on drug interactions.

Front View of the National Institute for Korean Medicine Development

Front View of the National Institute for Korean Medicine Development

View original image

Since its launch in 2019, the portal has recorded a cumulative total of approximately 1.09 million visitors and 1 million data downloads up to 2025.


With this revision, the previous membership grading system—which categorized users as Korean medicine doctors, students, or the general public—has been abolished, and the registration process has been unified for all users.


Additionally, by expanding the scope of public access to key information, clinical practice guidelines and research results can now be utilized more freely.


The institute also plans to further increase usability by providing curated content and summaries of outstanding research achievements in the future.


Suhyun Kwon, Head of R&D Planning Team, stated, "We will strengthen system features to lower barriers to use, so that the accumulated research achievements can be widely utilized in the field."


Meanwhile, to commemorate the revision, the institute will distribute 100 free copies of four different editions of the ‘Korean Medicine Standard Clinical Practice Guideline Key Summary Booklets’ to the first applicants.



Applications will be accepted on a first-come, first-served basis starting August 13 through the NCKM homepage.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing